As part of our ongoing aim to bring you reports of new developments, we have added a review of a patient satisfaction study of nasal spray treatments of Olopatadine Hydrochloride/Mometasone Furoate Monohydrate and Azelastine Hydrochloride/Fluticasone Propionate for allergic rhinitis in Australia.
Independent commentary is provided by Professor Alkis Psaltis, Head of Department of Otolaryngology Head and Neck Surgery at the Queen Elizabeth Hospital in Adelaide, and Dr Biljana Cvetkovski, a researcher at the Woolcock Institute of Medical Research.
Please login below to download this issue (PDF)